Combined Blood and Genetic Tests Estimate Timing of Alzheimer’s Symptom Onset
Posted on 14 Sep 2026
Predicting when Alzheimer’s disease will manifest remains a major clinical challenge, particularly before cognitive decline is evident. Blood biomarkers and genetic risk markers can flag elevated risk, but they rarely translate into actionable timelines for onset. More precise forecasting could refine patient counseling and optimize enrollment for prevention trials. A new study shows that combining a blood-based Alzheimer’s marker with genetic risk testing can estimate when first symptoms may appear in asymptomatic, high-risk adults.
Columbia University Irving Medical Center (CUIMC; New York, NY, USA) investigators evaluated a combined approach pairing a plasma phosphorylated tau 217 (p-tau217) blood test with apolipoprotein E (APOE) genotyping to forecast the onset of Alzheimer’s symptoms. The p-tau217 biomarker reflects amyloid and tau pathology in the brain and is increasingly used to help confirm or rule out Alzheimer’s disease in older adults with memory loss or cognitive decline. Since elevated p-tau217 can also be detected before symptoms appear but has limited predictive power on its own, the team assessed whether adding APOE risk status would improve prognostication.
The findings, published on September 9, 2026, in The Lancet Neurology, draw on data from roughly 8,500 participants spanning different ethnic backgrounds. As described in the paper title, the analysis pooled prospective cohort studies across diverse racial and ethnic groups. Investigators examined whether integrating a blood-based disease biomarker with a genetic risk variant (APOE4) could provide clinically useful timelines for symptom emergence among people not currently experiencing cognitive impairment.
Results indicated that once p‑tau217 levels become elevated, individuals carrying one or more copies of the high‑risk APOE4 variant are likely to develop symptoms in approximately three to four years. Those with other APOE variants are expected to develop symptoms in about five to six years. These projections were derived from the combined testing paradigm and are intended to inform timing rather than diagnose current disease in asymptomatic individuals.
The study cites collaboration and data contributions from institutions including CEDIMAT and Universidad Pedro Henríquez Ureña (Dominican Republic), Pontificia Universidad Católica Madre y Maestra (Dominican Republic), the University of Wisconsin-Madison, Rush University Medical Center, the University of North Texas Health Science Center, and the Alzheimer’s Disease Neuroimaging Initiative.
According to the authors, the approach could help physicians determine when to prescribe preventive treatments now in development. A study is already underway to assess whether antibody drugs can slow disease progression when given to asymptomatic people with elevated p-tau217, and the current findings are expected to inform future clinical trials.
“The combination of the tests really makes a difference in predictive power. And the projections are the same for everyone regardless of their background,” said Richard Mayeux, chair of the Department of Neurology at Columbia University Vagelos College of Physicians and Surgeons and neurologist-in-chief at NewYork-Presbyterian/Columbia University Irving Medical Center.
“If you have a drug that could prevent disease, what would be the optimal time to give it to people? Our data is telling us, for people at high risk with APOE4 genes, the best time is when their ptau levels elevate, about three years before symptoms emerge,” said Mayeux.
Related Links
Columbia University Irving Medical Center
